Concord Medical(US:CCM) Jin Rong Jie·2025-08-06 13:46Core Insights - Taihe Cheng Medical (CCM) opened with a 5.94% increase, reaching $5.35 per share, with a total market capitalization of $26.54 million [1] - As of December 31, 2024, the company's total revenue is projected to be 384 million RMB, a year-on-year decrease of 28.55%, while the net profit attributable to the parent company is expected to be -30.8 million RMB, a decrease of 3.56% year-on-year [1] Company Overview - Taihe Cheng Medical Group Co., Ltd. is a holding company primarily engaged in medical services, listed on the New York Stock Exchange in 2009, recommended by JP Morgan, Morgan Stanley, and CICC [1] - Established in 1997, the company specializes in cancer prevention, diagnosis, education, and research, offering third-party tumor imaging diagnosis and radiation therapy services, as well as operating specialized cancer hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on diagnostic technology, radiation quality control, medical processes, operational management, brand usage in Singapore and mainland China, and the operation and training of proton centers [1] - The collaboration aims to build an international specialized cancer hospital based on a multidisciplinary treatment model and clinical research orientation, enhancing patient experience and improving cancer treatment standards in China [1]